Legend Biotech Follow-On - A Little Opportunistic. Last Deal Did Well, After a Large Correction
Legend Biotech Corp (LEGN US), a non-wholly owned subsidiary of Hong Kong-listed Genscript Biotech (1548 HK), is planning to raise up to US$250m in...
426 Views
Genscript Biotech - Commercialized CAR-T & Strong CGT CDMO Indicate Exponential Growth in Valuation
GenScript’s commercialization of CAR-T, rapid growing GCT CDMO and “all-in” on GCT industry chain indicate exponential growth potential in...
448 Views
China Healthcare Weekly (May.27) - New TAVR Policy, Exiting Issue of COVID Testing, RemeGen/Keymed
New TAVR policy will break the low demand bottleneck due to high cost; COVID testing industry faces the problem of exit; Remegen/Keymed may have...
459 Views
China Healthcare Weekly (May.6)-FDA’s CRL on Junshi/HCM, Biotech Globalization, Significance of DRGs
The FDA announced its CRL on Hutchmed’s surufatinib and Junshi’s PD-1. It's time to reexamine the logic and prospects of biotech globalization. The...
368 Views
Legend Biotech Corp (LEGN US): Carvykti Approval Is the Silver Lining Amid Uncertainty of Delisting
FDA approval of the company’s first drug Carvykti, with initial peak sales opportunity of $1.5 billion should be considered as a buy opportunity,...
893 Views